Table 5.
Clinical and pathological characteristics of all the patients.
| Characteristics | All patients (n = 2573) | % |
|---|---|---|
| Age at diagnosis, y | ||
| <40 | 329 | 12.8 |
| 40-60 | 1779 | 69.1 |
| >60 | 465 | 18.1 |
| Tumour stage | ||
| T1 | 1192 | 46.3 |
| T2 | 1275 | 49.6 |
| T3 | 53 | 2.1 |
| Tx | 53 | 2.1 |
| Lymph stage | ||
| N0 | 871 | 33.9 |
| N1 | 1177 | 45.7 |
| N2 | 301 | 11.7 |
| N3 | 224 | 8.7 |
| LVI | ||
| Negative | 1515 | 58.9 |
| Positive | 940 | 36.5 |
| Unknown | 118 | 4.6 |
| IHC-based subtypes | ||
| Luminal-like | 1594 | 61.9 |
| HER2-positive | 693 | 26.9 |
| TNBC | 286 | 11.1 |
| Histological grade | ||
| Grade 1, 2 | 1709 | 66.4 |
| Grade 3 | 864 | 33.6 |
| Ki-67* | ||
| Low | 1170 | 45.5 |
| High | 1403 | 54.5 |
| Recurrence status | ||
| Yes | 248 | 9.6 |
| No | 2325 | 90.4 |
Abbreviations: LVI, lymphatic vessel invasion; IHC-based, immunohistochemical-based; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.
*Ki-67 median value = 15%, Ki-67 Low <15%, Ki-67 High ≥ 15%.